Home › Kanser sa Suso › Florida › Plantation
Pag-aaral pangklinika para sa Kanser sa Suso sa Plantation, FL
14 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Plantation (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Nagre-recruitPhase 3
- Research Site, Plantation
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Nagre-recruitPhase 3
- Miami Cancer Institute, Plantation
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Nagre-recruitPhase 3
- Miami Cancer Institute at Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Nagre-recruitPhase 3
- University of Miami-SCCC-Plantation, Plantation
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- Miami Cancer Institute at Plantation, Plantation
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Nagre-recruitPhase 2
- Miami Cancer Institute - Plantation (MCIP), Plantation
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Nagre-recruitPhase 3
- Miami Cancer Institute Plantation, Plantation
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Nagre-recruitPhase 3
- BRCR Medical Center, Inc- Internal Medicine, Plantation
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Nagre-recruitPhase 2
- Miami Cancer Institute at Baptist Health, Plantation
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- BRCR Global, Plantation
- Florida Clinical Trials Group, Plantation
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- BRCR global, Plantation
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Nagre-recruitObservasyonal na pag-aaral
- Baptist Cancer Care - Plantation, Plantation
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Plantation
- Non-Small Cell Lung Cancer16 pag-aaral
- Kanser (lahat ng uri)7 pag-aaral
- Lupus7 pag-aaral
- Kanser sa Baga7 pag-aaral
- Metastatic Cancer6 pag-aaral
- Rheumatoid Arthritis6 pag-aaral
- Kanser sa Prostate5 pag-aaral
- Psoriatic Arthritis5 pag-aaral
- Colorectal Cancer5 pag-aaral
- Melanoma4 pag-aaral
- Multiple Myeloma4 pag-aaral
- Small Cell Lung Cancer4 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.